Scienture Holdings, INC 8-K filings

TRxADE Health, Inc. announced the appointment of Subbarao Jayanthi to its board of directors and the resignation of Narasimhan Mani, both effective June 17, 2024.

TRxADE Health received a Nasdaq notice for failing to file its quarterly report on time and appointed two new directors while two others resigned.

TRxADE Health has delayed its quarterly report filing but believes it meets the minimum stockholders' equity requirement for Nasdaq listing.

TRxADE Health, Inc. declared a special cash dividend of $8.00 per share, funded by proceeds from the sale of its web-based market platform assets, and also divested its subsidiary Superlatus Inc.

TRxADE Health, Inc. has agreed to sell its web-based market platform business to Micro Merchant Systems, Inc. for $22.5 million in cash, with a potential additional $7.5 million performance-based payment.

TRxADE Health has filed its delayed quarterly report, regaining compliance with Nasdaq listing rules after a previous non-compliance notice.

TRxADE Health, Inc. amended its merger agreement with Superlatus, Inc. after Superlatus failed to meet a post-closing condition, resulting in an adjustment to the merger consideration.